We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
6 peer-reviewed studies
What the evidence says
Most Selegiline studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 1996–2025 with a typical study size of 18 participants.
Based on 6 studies · 1 meta-analysis · 18 total participants
Confidence
ModerateBy outcome
1 study in the last 5 years · Latest meta-analysis: 2025
A 2025 meta-analysis of 22 longevity experiments concluded that l-deprenyl reproducibly extends lifespan across mammalian species.
Bene · Ageing research reviews (2025)
Long-term low-dose (-)deprenyl extended lifespan in ovariectomized female rats compared with saline controls.
Dalló, Köles · Acta physiologica Hungarica (1996)
The effects of deprenyl on longevity and antioxidant defenses are reviewed across animal species, with mixed lifespan findings.
Kitani, Kanai, Ivy, Carrillo · Annals of the New York Academy of Sciences (1998)
Long-term l-deprenyl in male Fischer 344 rats was assessed for effects on longevity and sensorimotor/learning function.
Bickford, Adams, Boyson, Curella, Gerhardt, Heron · Neurobiology of aging (1997)
Propargylamines such as deprenyl are reviewed as candidate pharmacological interventions in aging and age-associated disorders.
Kitani, Minami, Yamamoto, Kanai, Ivy, Carrillo · Annals of the New York Academy of Sciences (2002)
Neuroprotection by propargylamines in Parkinson's disease involves suppression of apoptosis and induction of pro-survival factors.
Maruyama, Akao, Carrillo, Kitani, Youdium, Naoi · Neurotoxicology and teratology (2002)